Pathogen inactivation: A new paradigm for preventing transfusion- transmitted infections

American Journal of Clinical Pathology

Volumn 128, Issue 6, 2007, Pages 945-955

  McCullough, Jeffrey ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Blood safety; Pathogen inactivation; Transfusion transmitted infection

Indexed keywords

ALKYLATING AGENT; AMOTOSALEN; DETERGENT; FRESH FROZEN PLASMA; METHYLENE BLUE; PLASMA PROTEIN; RIBOFLAVIN; ANTIINFECTIVE AGENT; PHOTOSENSITIZING AGENT; PSORALEN DERIVATIVE; S 59, PSORALEN; S-59, PSORALEN; UNCLASSIFIED DRUG;

APHERESIS; ARTICLE; CELL FUNCTION; CLINICAL TRIAL; DNA DAMAGE; ERYTHROCYTE; GRAFT VERSUS HOST REACTION; HUMAN; INFECTION; LABORATORY TEST; PATHOGENESIS; PRIORITY JOURNAL; TRANSFUSION TRANSMITTED INFECTION; BLOOD BANK; BLOOD TRANSFUSION; BLOODBORNE BACTERIUM; INFECTION CONTROL; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ALKYLATING AGENTS; ANTI-INFECTIVE AGENTS; BLOOD BANKS; BLOOD TRANSFUSION; BLOOD-BORNE PATHOGENS; COMMUNICABLE DISEASE CONTROL; DETERGENTS; HUMANS; METHYLENE BLUE; PHOTOSENSITIZING AGENTS; PSORALENS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIBOFLAVIN;

EID: 38049093769     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/RAPQ3NXG3MV9AL94     Document Type: Article

References (103)

1. Muller-Breitkreutz K, Mohr H. Hepatitis C and human immunodeficiency virus RNA degradation by methylene blue/light treatment of human plasma. J Med Virol. 1998;56:239-245.
2. Wagner SJ. Virus inactivation in blood components by photoactive phenothiazine dyes. Transfus Med Rev. 2002;16:61-66.
3. Zeiler T, Riess H, Wittmann G, et al. The effect of methylene blue phototreatment of plasma proteins and in vitro coagulation capability of single-donor fresh-frozen plasma. Transfusion. 1994;34:685-689.
4. Lambrech B, Mohr H, Knuver-hopf J, et al. Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light. Vox Sang. 1991;60:207-213.
5. Morrado M, Villar A, Jimenez-Yuste VM, et al. Effects of methylene blue-treated plasma on coagulation factors [abstract]. Blood. 1999;94:247a.
6. Kumar VK, Lockerbi O, Keil SD, et al. Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem Photobiol. 2004;80:15-21.
7. Tsugita A, Okada Y, Uehara K. Photosensitized inactivation of ribonucleic acids in the presence of riboflavin. Biochim Bhphvs Acta. 1965;103:360-563.
8. Korycka-Dahl M, Richardson T. Photodegradation of DNA with fluorescent light in the presence of riboflavin, and photoprotection by flavin triplet-state quenchers. Biochim Biophys Acta. 1980;610:229-234.
9. Hardwick CC, Herivel TR, Hernandez SC, et al. Separation, identification and quantification of riboflavin and its photoproducts in blood products using high-performance liquid chromatography with fluorescence detection: a method to support pathogen reduction technology. Photochem Photobiol. 2004;80:609-615.
10. Wollowitz S. Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma. Semin Hematol. 2001;38:4-11.
11. Wollowitz S. Targeting DNA and RNA in pathogens: mode of action of amotosalen HCI. Transfus Med Hemother. 2004;31:11-16.
12. Cook D, Stassinopoulos A, Wallowitz S, et al. In vivo analysis of packed red blood cells treated with S-303 to inactivate pathogens. Blood. 1998;92(suppl 1):503a.
13. Dupuis K, Alfonsol A. Helinx technology used in the INTERCEPT blood system, inactivates high titers of emerging insect-borne pathogens in platelets and red cells [abstract]. Blood Banking Transfusion Med. 2003;1(suppl 1):S292.
14. Ciaravino V. Preclinical safety of a nucleic acid-targeted Helinx component: a clinical perspective. Semin Hematol. 2001;38:12-19.
15. Ciaravino V, McCullough T, Dayan AF. Pharmacokinetic and toxicology assessment of INTERCEPT (S-59 and UVA treated) platelets. Hum Exp Toxicol. 2001;20:533-550.
16. Ciaravino V, McCullough T, Cimino G. The role of toxicology assessment in transfusion medicine. Transfusion. 2003;34:1481-1492.
17. Ciaravino V, McCullough T, Cimino G, et al. Preclinical safety profile of plasma prepared using the INTERCEPT Blood System. Vox Sang. 2003;85:171-182.
18. Lin L, Conlan MG, Tessman J, et al. Amotosalen interactions with platelet and plasma components: absence of neoantigen formation after photochemical treatment. Transfusion. 2005;45:1610-1620.
19. Conlan MG, Corash L, Flament J, et al, for the euroSPRITE SPRINT, and STEP Study Groups. Intercept platelets and plasma do not result in neoantigenicity: result of seven phase 3 clinical trials [abstract]. Vox Sang. 2004;87:6.
20. Reddy H, Dayan AD, Cavagnaro J, et al. Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white cell inactivation (Mirasol PRT™ System). Transfus Med Rev. In press.
21. Ciaravino V, Stassinopoulos A, Singh Y, et al. INTERCEPT red blood cells are not genotoxic or carcinogenic in a series of in vitro and in vivo tests. Blood. 2002;100(suppl 1):143b.
22. Ciaravino V, McCullough T, Woods N, et al. Absence of carcinogenicity in a 26-week intravenous study with S-303-treated mouse red blood cells in C57BL/6TAC-TRP53TML heterozygote mice [abstract]. Blood Banking Transfusion Med. 2003;1(suppl 1):S365.
23. Lin L, Cook DN, Wiesehahn GP, et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion. 1997;37:423-435.
24. Lin L, Alfonso R, Behrman B, et al. Photochemical treatment of platelet concentrates with a novel psoralen and UVA to enhance the safety of platelet transfusion. Infusion Ther Transfusion Med. 1998;25:39-48.
25. Lin L, Corten L, Murthy KK, et al. Photochemical inactivation of hepatitis B (HBV) and hepatitis C (HCV) virus in human platelet concentrates as assessed by a chimpanzee infectivity model [abstract]. Blood. 1998;92:502a.
26. Van Voorhis WC, Barrett LK, Eastman T, et al. Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCI) and long-wavelength UV. Antimicrob Agents Chemother. 2003;47:475-479.
27. Van Voorhis W, Barrett L, Eastman T, et al. Helinx inactivates the malaria, Chagas' disease and leishmaniasis protozoa in human platelet concentrates [abstract]. Blood. 2002;100:708a.
28. Sawyer L, Dupuis K, Alfonso R, et al. The INTERCEPT Blood System for platelets inactivates high titers of a variety of bloodborne pathogens in platelets [abstract]. Hematol J. 2003;4:228.
29. Lin L, Hanson CV, Alter HJ, et al. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion. 2005;45:580-590.
30. Eastlman RT, Barrett LK, Dupuis K, et al. Leishmania inactivation in human pheresis platelets by a psoralen (amotosalen HCI) and long-wavelength ultraviolet irradiation. Transfusion. 2005;45:1459-1463.
31. Lin L, Dikeman R, Molini B, et al. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion. 2004;44:1496-1504.
32. Pinna D, Sampson-Johannes A, Clementi M, et al. Amotosalen photochemical inactivation of severe acute respiratory syndrome coronavirus in human platelet concentrates. Transfus Med. 2005;15:269-276.
33. Roback JD, Conlan M, Drew WL, et al. The role of photochemical treatment with amotosalen and UVA light in the prevention of transfusion-transmitted cytomegalovirus infections. Transfus Med Rev. 2006;20:45-56.
34. McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood. 2004;104:1534-1541.
35. Sawyer L, Hanson D, Castro G, et al. Inactivation of parvovirus B19 in human platelet concentrates by treatment with amotosalen and ultraviolet A illumination. Transfusion. 2007;47:1062-1070.
36. Ruane PH, Edrich R, Gampp D, et al. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion. 2004;44:877-885.
37. Goodrich L, Ghielli M, Hansen E, et al. Riboflavin and UV light inactivate enveloped and non-enveloped viruses in platelet concentrates under conditions which maintain cell quality [abstract]. Vox Sang. 2002;83:111. Abstract 333.
38. Li J, de Korte D, Woolum MD, et al. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products. Vox Sang. 2004;87:82-90.
39. Goodrich L, Douglas I, Urioste M. Riboflavin photoinactivation procedure inactivates significant levels of bacteria and produced a culture negative product [abstract]. Transfusion. 2002;42:16S.
40. Goodrich RP. The use of riboflavin for the inactivation of pathogens in blood products. Vox Sang. 2000;78:211-215.
41. Goodrich RP, Li J, Edrich R, et al. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apheresis Sci. 2006;35:5-17.
42. Goodrich RP, Edrich RA, Goodrich LL, et al. The antiviral and antibacterial properties of riboflavin and light: applications to blood safety and transfusion medicine. In: Silva E, Edwards AM, eds. Flavins: Photochemistry and Photobiology. Cambridge, England: Royal Society of Chemistry; 2006. Comprehensive Series in Photochemistry and Photobiology; Vol 6.
43. Cardo LJ, Rentas FJ, Ketchum L, et al. Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and light. Vox Sang. 2006;90:85-91.
44. Sawyer LR, Mababangloob R, Patel N, et al. Inactivation of pathogens in red blood cells by a modified treatment process utilizing S-303 and glutathione [abstract]. Vox Sang. 2006;91(suppl 3):31-32.
45. Cook D, Stassinopoulos A, Merritt J, et al. Inactivation of pathogens in packed red blood cell (PRBC) concentrates using S-303 [abstract]. Blood. 1997;90:409a.
46. Grass JA, Hei DJ, Metchette K, et al. Inactivation of leukocytes in platelet concentrates by psoralen plus UVA. Blood. 1998;91:2180-2188.
47. Corash L, Lin L. Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease. Bone Marrow Transplant. 2004;33:1-7.
48. Fiebig E, Hirschkorn DF, Maino VC, et al. Assessment of donor T-cell function in cellular blood components by the CD69 induction assay: effects of storage, gamma radiation, and photochemical treatment. Transfusion. 2000;40:761-770.
49. Grass JA, Wafa T, Reames A, et al. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood. 1999;93:3140-3147.
50. Fast LD, DiLeone G, Cardarelli G, et al. Mirasol PRT treatment of donor white blood cells prevents the development of xenogeneic graft-versus-host disease in Rag 2-/-γc-/- double knockout mice. Transfusion. 2006;46:1553-1560.
51. Fast LD, DiLeone G, Li J, et al. Functional inactivation of white blood cells by Mirasol treatment. Transfusion. 2006;46:642-648.
52. Conlani M, Lin J-S, Flament J, et al. INTERCEPT platelets treated with Helinx technology to inactivate T-cells prevented transfusion-associated graft vs host disease (TAGVHD): results of 3 clinical trials. Blood Banking Transfusion Med. 2003;1(suppl 1):S292.
53. Osselaer JC, Doyen C, Messe N, et al. Routine use of platelet components prepared with photochemical treatment (INTERCEPT platelets): impact on clinical outcomes and resources [abstract]. Blood. 2005;106(11):129a.
54. Van Haure I, Benoit M, Bardon V. Therapeutic efficacy and safety of transfusion of pathogen inactivated platelets to pediatric patients [abstract]. Vox Sang. 2006;91(suppl 3):177.
55. Janetzko K, Klinger M, Mayaudon V, et al. Storage characteristics of split double-dose platelet concentrates derived from apheresis and treated with amotosalen hydrochloride and UVA light for pathogen inactivation. Transfus Med Hemother. 2002;29:193-198.
56. Knurson F, Alfonso R, Dupuis K, et al. Photochemical inactivation of bacteria and HIV in buffy-coat-derived platelet concentrates under conditions that preserve in vitro platelet function. Vox Sang. 2000;78:209-216.
57. Picker SM, Speer R, Gathot BS. Functional characteristics of butty-coat PLTs photochemically treated with amotosalen-HCI tor pathogen inactivation. Transfusion. 2004;44:520-529.
58. van Rhenen DJ, Vermeij J, Mayaudon V, et al. Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats. Vox Sang. 2000;79:206-214.
59. Lm C, Bardossy L, Drerup J, et al. Demonstration of in vivo hemostatic efficacy of human PC-T platelets using a thrombocytopenic rabbit bleeding time model [abstract]. Vox Sang. 2000;78(suppl 1). Abstract 0098.
60. Pyke AD, Blajchman MA. The pathogen inactivation of platelets: studies of the possible mechanisms of the platelet dysfunction seen following photochemical treatment [abstract]. Blood. 2006;108:175a.
61. Hambleton J, Wages D, Radu-Radulescu L, et al. Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin. Transfusion. 2002;42:1302-1307.
62. Cazenave JP, Isola H, Wiesel ML, et al. Stability of coagulation factors in plasma prepared with photochemical treatment (INTERCEPT™) stored for one year [abstract|. Vox Sang. 2006;91(suppl 3):185.
63. Singh Y, Sawyer LS, Pinkoski LS, et al. Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion. 2006;46:1168-1177.
64. Corten L, Wiesehahn GP, Smyers JM, et al. Photochemical inactivation of hepatitis B and hepatitis C viruses in human plasma as assessed in a chimpanzee infectivitv model [abstract]. Blood. 2000;96:60a.
65. Goodrich RP, Janssen M, Ghielli M, et al. Correlation of in vitro parameters and in vivo recovery and survival values for PRT treated platelets in normal human donors. Transfusion. 2003;43:79A.
66. Buytaert-Hoefen KA, Hendrix B, Gampp D, et al. Protein quality in Mirasol treated fresh frozen plasma. Transfusion. 2006;46(suppl):114A.
67. Buytaert-Hoefen KA, Gampp D, Edrich R, et al. Mirasol pathogen reduction treated fresh frozen plasma maintains protein quality. Vox Sang. 2006;91(suppl 3):183.
68. Corash L. Inactivation of viruses, bacteria, protozoa and leukocytes in platelet and red cell concentrates. Vox Sang. 2000;78:205-210.
69. 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCI (S-59) and ultraviolet A light. Transfusion. 2004;44:1732-1740.
70. Corash L, Behrman B, Rheinschmidt M, et al. Post-transfusion viability and tolerability of photochemically treated platelet concentrates [abstract]. Blood. 1997;90:267a.
71. Slichter SJ, Corash L, Grabowski M, et al. Viability and hemostatic function of photochemically-treated platelets in thrombocytopenic patients [abstract]. Blood. 1999;94:376a.
72. Slichter SJ, Raife TJ, Davis K, et al. Platelets photochemically treated with amotosalen HCI and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia. Transfusion. 2006;46:731-740.
73. AuBuchon JP, Herschel L, Roger J, et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion. 2005;45:1535-1341.
74. Wages D, Smith D, Walsh J, et al. Transfusion of therapeutic doses of virallv inactivated fresh frozen plasma in healthy subjects [abstract]. Blood. 1997;90:409a.
75. Greenwalt TJ, Hambleton J, Wages D, et al. Viability of red blood cells treated with a novel pathogen inactivation system [abstract]. Transfusion. 1999;39:109s.
76. Hambleton J, Greenwalt T, Viele M, et al. Post transfusion recovery after multiple exposures to red blood cell concentrates (RBCs) treated with a novel pathogen inactivation process [abstract]. Blood. 1999;94:376a.
77. Rios JA, Hambleton J, et al. Viability of red cells prepared with S-503 pathogen inactivation treatment. Transfusion. 2006;46:1778-1786.
78. van Rhenen D, Gulliksson H, Cazenave JP, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood. 2003;101:2426-2433.
79. Pineda A, McCullough J, Benjamin RJ, et al. Pathogen inactivation of platelets using a photochemical treatment with amotosalen HCl and ultraviolet light: process used in the SPRINT Trial. Transfusion. 2006;46:562-571.
80. Murphy S, Snyder E, Cable R, et al. Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT Trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light. Transfusion. 2006;46:24-33.
81. Cazenave JP. Clinical experience with pathogen inactivated platelets. Presented at: Pathogen Inactivation: Making Decisions About New Technologies Consensus Conference; March 29-30, 2007; Toronto, Canada.
82. Snyder E, McCullough J, Slichter SJ, et al. Clinical safety of platelets photochemically treated with amotosalen HCI and ultraviolet A light for pathogen inactivation: the SPRINT Trial. Transfusion. 2005;45:1864-1875.
83. Mintz PD, Bass NM, Petz LD, et al. Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease. Blood. 2006;107:3753-3760.
84. Wages DC, Bass N, Keefe E, et al. Treatment of acquired coagulopathy by transfusion of fresh frozen plasma (FFP) prepared using a novel, single unit photochemical pathogen inactivation process [abstract]. Blood. 1999;94:247a.
85. deAlarcon P, Benjamin R, Shopnick R, et al. An open-label trial of fresh frozen plasma treated by the Helinx™ single-unit photochemical pathogen inactivation system in patients with congenital coagulation factor deficiencies [abstract]. Blood. 2000;96:61a.
86. de Alarcon P, Benjamin R, Dugdale M, et al. Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation (PCT-FFP): transfusion of patients with congenital coagulation factor deficiencies. Transfusion. 2005;45:1362-1372.
87. Mintz PD, Neff A, Mackenzie M, et al. A randomized, controlled phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion. 2006;46:1693-1704.
88. Benjamin RJ, McCullough J, Mintz PD, et al. Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a phase III clinical trial in cardiac surgery patients. Transfusion. 2005;45:1730-1749.
89. North A, Garratty G, Schott MA, et al. A modified treatment process for preparation of S-303 RBC for pathogen inactivation substantially reduces the potential for cross-reactivity [abstract]. Vox Sang. 2006;91(suppl 3):126.
90. Peterson LR, Epstein JS. Problem solved? West Nile virus and transfusion safety [editorial]. N Engl J Med. 2005;353:516-517.
91. Biggerstaff BJ, Petersen LR. Estimated risk of transmission of the West Nile virus through blood transfusion in the US, 2002. Transfusion. 2003;43:1007-1017.
92. Pealer LN, Marfin AA, Petersen LR, et al. Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med. 2003;349:1236-1245.
93. Custer B, Busch MP, Marfin AA, et al. The cost-effectiveness of screening the US blood supply for West Nile virus. Ann Intern Med. 2005;143:486-492.
94. Charrel RN, de Lamballerie X, Raoult D. Chikungunya outbreaks: the globalization of vectorborne diseases. N Engl J Med. 2007;356:769-771.
95. Sawyer L, Dupuis K, Sampson-Johannes A, et al. Inactivation of Chikungunya virus in plasma and platelets using Helinx technology, as utilized in the INTERCEPT Blood System [abstract]. Vox Sang. 2006;91(suppl 3):74.
96. Rasongles P, Isola H, Kientz D, et al. Rapid implementation of photochemical pathogen inactivation (INTERCEPT) for preparation of platelet components during an epidemic of Chikungunya virus [abstract]. Vox Sang. 2006;91(suppl 3):32.
97. Farnon E. Update: Chikungunya fever diagnosed among international travelers: United States, 2006. MMWR Morb Mortal Wkly Rep. 2007;56:276-277.
98. Eder AF, Weiss JW, Notari EP, et al. Residual risk of septic transfusion reactions from bacterially-screened platelets, pheresis linked to double-needle collection procedures [abstract]. Transfusion. 2006;46:1A.
99. Bowden RA, Slichter SJ, Sayers M, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood. 1995;86:3598-3603.
100. Hewlett IK, Epstein JS. Food and drug administration conference on the feasibility of genetic technology to close the HIV window in donor screening. Transfusion. 1997;37:346-351.
101. McCullough J. Blood donor medical assessment and blood collection. In: Transfusion Medicine. 2nd ed. Philadelphia, PA: Elsevier Churchill Livingstone; 2005:53-75.
102. Psaty BM, Burke S. Institute of Medicine on drug safety. N Engl J Med. 2006;355:1753-1759.
103. Bennett CL, Nebeker JR, Lyons E, et al. The Research on Adverse Drug Events and Reports (RADAR) project. JAMA. 2005;293:2131-2140.